Should You Buy Kamada Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Kamada Ltd. (KMDA) sits in the bottom tier of our quality coverage with a score of 2.6/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $8.09.
The short answer: 1 of 2 CirclFi valuation models project upside for Kamada Ltd. (KMDA) at $8.09 — the models are evenly split, with a Quality Score of 2.6/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Kamada Ltd. (KMDA) in 2026?
What Is the Bull Case vs the Bear Case for Kamada Ltd. (KMDA)?
| Bull case — $11.67 target (+44.2%) | Bear case — $3.39 target (-58.1%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $11.67 (+44.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Quality of Company (QOC) framework, Kamada Ltd.'s rating of 2.6/10 indicates below-average quality, raising questions about sustainable earnings levels. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Kamada Ltd.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $3.39 (-58.1%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +102.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. | |
| Industry headwind: drug pricing legislation represents a meaningful risk for Kamada Ltd. and its Drug Manufacturers - Specialty & Generic peers. |
How Does KMDA Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: HCM · BGM · GCAN · UPC · CTTH · SXTC · CRON · SCYX · APUS · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like KMDA on Quality?
Closest companies to KMDA’s Quality of Company score of 2.6/10, across all industries.
- SNTG — Sentage Holdings Inc. (QOC 2.6) · analysis
- APWC — Asia Pacific Wire & Cable Corporation Limited (QOC 2.6) · analysis
- EGG — Enigmatig Limited (QOC 2.6) · analysis
- CNL — Collective Mining Ltd. (QOC 2.6) · analysis
- ICL — ICL Group Ltd (QOC 2.6) · analysis
- ZKIN — ZK International Group Co., Ltd. (QOC 2.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does KMDA Appear In?
So Is Kamada Ltd. (KMDA) Worth Buying in 2026?
Our models don't have a clear verdict on Kamada Ltd.. At $8.09 vs. $7.53 median fair value, the median upside of -6.9% masks significant model disagreement (+102.3% spread). With quality at 2.6/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Kamada Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About KMDA Stock?
Should I buy KMDA stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for KMDA at $8.09. The models are divided, which means the investment case depends heavily on your assumptions about Kamada Ltd.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Kamada Ltd.?
Key risks include: a below-average Quality Score of 2.6/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (244% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does KMDA compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, KMDA holds a Quality Score of 2.6/10. Comparable companies include HCM (QOC 2.7), BGM (QOC 1.9), GCAN (QOC 3.1). The relative ranking helps investors identify whether KMDA offers better fundamental quality than alternatives in the same sector.
Is KMDA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. KMDA's Quality Score of 2.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy KMDA at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $3.39 to $11.67. At $8.09, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for KMDA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad